将来への賭け：リンパ腫患者のためのBET阻害薬
Timothy J Voorhees1, Catherine C Coombs2
1Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Med (New York, N.Y.)
|January 10, 2026
Abstract:
Despite available treatments, patients with lymphoma may still develop relapsed or refractory diseases, highlighting the need for new therapies. Zhang et al.1 report a phase I dose-escalation study of TQB3617, a novel BET inhibitor, in diverse lymphoma subtypes. The study showed promising safety and efficacy, including T cell and Hodgkin lymphoma, warranting further investigation.
関連する概念動画
02:34Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K